Related Experiment Video
Updated: Jun 3, 2026

07:17
Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis
Published on: August 17, 2022
Bioimpedance analysis: should it be used in morbid obesity?
Ana A D Leal1, Joel Faintuch, Alvaro A C Morais
1Institute Dr. João A B Noe, Vitória, ES, Brazil.
Summary
Bioimpedance analysis (BIA) shows reliable body composition assessment in morbidly obese females but not males. It complements anthropometry for monitoring metabolic health and weight loss in bariatric candidates.
Area of Science:
- Obesity research
- Clinical nutrition
- Body composition analysis
Background:
- Bioimpedance analysis (BIA) reliability in morbidly obese individuals is debated.
- Metabolic implications may warrant re-evaluation of BIA's utility.
- Previous concerns have limited BIA's application in this population.
Purpose of the Study:
- To investigate anthropometric and clinical associations of BIA in bariatric candidates.
- To assess the reliability of BIA in morbidly obese individuals.
- To explore BIA's role in metabolic health assessment.
Main Methods:
- Prospective study of 94 bariatric candidates (mean BMI 40.8 kg/m²).
- Utilized single-frequency BIA, anthropometrics, inflammatory indices, and biochemical profiles.
- Included participants with and without metabolic syndrome.
Main Results:
- BIA body composition (water, fat) consistent with literature in females, not males.
- Strong associations found between BIA, anthropometrics (BMI, waist circumference), and inflammatory markers (ferritin, CRP) in both genders.
- Multivariate analysis showed BIA and anthropometry complement each other as metabolic markers.
Conclusions:
- BIA limitations primarily affect males, not females.
- BIA demonstrates good associations with anthropometry and metabolic indices (liver enzymes, carbohydrate, lipid metabolism).
- BIA warrants further investigation for liver steatosis and inflammation, potentially aiding weight loss and metabolic risk monitoring alongside anthropometry.
Related Concept Videos
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
